Inflammation and bone loss in periodontal disease
- PMID: 18673012
- DOI: 10.1902/jop.2008.080233
Inflammation and bone loss in periodontal disease
Abstract
Inflammation and bone loss are hallmarks of periodontal disease (PD). The question is how the former leads to the latter. Accumulated evidence demonstrates that PD involves bacterially derived factors and antigens that stimulate a local inflammatory reaction and activation of the innate immune system. Proinflammatory molecules and cytokine networks play essential roles in this process. Interleukin-1 and tumor necrosis factor-alpha seem to be primary molecules that, in turn, influence cells in the lesion. Antigen-stimulated lymphocytes (B and T cells) also seem to be important. Eventually, a cascade of events leads to osteoclastogenesis and subsequent bone loss via the receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL)-osteoprotegerin (OPG) axis. This axis and its regulation are not unique to PD but rather are critical for pathologic lesions involving chronic inflammation. Multiple lines of evidence in models of PD clearly indicate that increases in RANKL mRNA expression and protein production increase the RANKL/OPG ratio and stimulate the differentiation of macrophage precursor cells into osteoclasts. They also stimulate the maturation and survival of the osteoclast, leading to bone loss. OPG mRNA expression and protein production do not generally seem to be increased in the periodontitis lesion. Studies of RANKL and OPG transgenic and knockout animals provide further support for the involvement of these molecules in the tissue loss observed in PD. Ironically, periodontal practitioners have focused on the bacterial etiology of PD and believed that plaque removal was aimed at eliminating specific bacteria or bacterial complexes. However, it seems that the reduction of inflammation and attenuation of the host's immune reaction to the microbial plaque, eventually leading to a decrease in the ratio of RANKL/OPG and a decrease in associated bone loss, are the actual and desired outcomes of periodontal therapy. Future therapeutic options are likely to have regulation of the RANK-RANKL-OPG axis as their goal.
Similar articles
-
Cytokine pattern determines the progression of experimental periodontal disease induced by Actinobacillus actinomycetemcomitans through the modulation of MMPs, RANKL, and their physiological inhibitors.Oral Microbiol Immunol. 2006 Feb;21(1):12-20. doi: 10.1111/j.1399-302X.2005.00245.x. Oral Microbiol Immunol. 2006. PMID: 16390336
-
Immune response: the key to bone resorption in periodontal disease.J Periodontol. 2005 Nov;76(11 Suppl):2033-41. doi: 10.1902/jop.2005.76.11-S.2033. J Periodontol. 2005. PMID: 16277573 Review.
-
Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.J Periodontal Res. 2006 Aug;41(4):354-60. doi: 10.1111/j.1600-0765.2006.00883.x. J Periodontal Res. 2006. PMID: 16827732
-
Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.Bone. 2004 Sep;35(3):629-35. doi: 10.1016/j.bone.2004.04.023. Bone. 2004. PMID: 15336598
-
Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.Medscape Womens Health. 2000 Mar;5(2):5. Medscape Womens Health. 2000. PMID: 10792853 Review.
Cited by
-
Proof-of-Principle Study Suggesting Potential Anti-Inflammatory Activity of Butyrate and Propionate in Periodontal Cells.Int J Mol Sci. 2022 Sep 20;23(19):11006. doi: 10.3390/ijms231911006. Int J Mol Sci. 2022. PMID: 36232340 Free PMC article.
-
Chronic consumption of alcohol increases alveolar bone loss.PLoS One. 2020 Aug 20;15(8):e0232731. doi: 10.1371/journal.pone.0232731. eCollection 2020. PLoS One. 2020. PMID: 32817640 Free PMC article.
-
Preparation and Evaluation of IL-1ra-Loaded Dextran/PLGA Microspheres for Inhibiting Periodontal Inflammation In Vitro.Inflammation. 2020 Feb;43(1):168-178. doi: 10.1007/s10753-019-01107-w. Inflammation. 2020. PMID: 31664694
-
Immuno-pathogenesis of Periodontal Disease: Current and Emerging Paradigms.Curr Oral Health Rep. 2014 Jun 1;1(2):124-132. doi: 10.1007/s40496-014-0017-8. Curr Oral Health Rep. 2014. PMID: 24839590 Free PMC article.
-
Osteoimmunomodulatory effects of biomaterial modification strategies on macrophage polarization and bone regeneration.Regen Biomater. 2020 Jun;7(3):233-245. doi: 10.1093/rb/rbaa006. Epub 2020 May 9. Regen Biomater. 2020. PMID: 32523726 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical